New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors
Research output: Patent
There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
| Original language | English |
|---|---|
| IPC | C07K 16/ 30 A I |
| Patent number | CN104768573 |
| Country/Territory | Denmark |
| Priority date | 03/05/2013 |
| Priority number | WO2013DK50126 |
| Publication status | Published - 8 Jul 2015 |
ID: 178221226